在 De Novo 和转换设置和风险缓解策略中调整 Belatacept 的免疫抑制
Richard N Formica1, Christian P Larsen2, Lionel Rostaing3
1Department of Medicine, Section of Nephrology and Transplantation, Yale School of Medicine, New Haven, CT.
Transplantation
|September 3, 2025
概括
在移植6个月后转换为贝拉的免疫抑制有效降低了急性排斥的风险. 这一策略与早期转换或 de novo belatacept 使用相比,保护了患者和的健康.
科学领域:
- 肝脏病学
- 免疫学
- 移植医学
背景情况:
- 卡尔西纽林抑制剂 (CNIs) 降低了排斥,但在移植患者中引起长期毒性.
- 贝拉塔塞普改善了功能和存活率,但具有更高的急性排斥 (AR) 风险.
- 移植后从CNI转换为贝拉塔塞普可以减轻AR,同时保持移植的健康.
研究的目的:
- 审查贝拉塔塞普治疗方案,重点关注从CNI转换的策略.
- 评估在特定患者群体中减轻AR风险和贝拉塔塞普相关结果的方法.
- 评估转换为基于贝拉塔塞普的免疫抑制的最佳时间.
主要方法:
- 对belatacept免疫抑制方案的临床试验和实践研究的综述.
- 对转换时间的数据分析 (移植后≥6个月与<6个月).
- 检查协议的修改,包括添加CNI或扩展缩.
主要成果:
- 移植后≥6个月使用贝拉塔塞普似乎有效降低AR风险.
- 早期转换 (< 6 个月) 或 de novo belatacept 使用与更高的AR率有关.
- 在转换过程中,延长的CNI治疗或延长的缩可能会进一步降低AR风险.
结论:
- 晚期转换 (≥6个月) 从CNI转换为贝拉塔塞普是接受移植患者的一个有希望的策略.
- 优化belatacept协议,特别是对于特殊人群,需要进一步的研究.
- 在基于贝拉的免疫抑制中,平衡AR风险和长期健康至关重要.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264
01:27Tumor Immunotherapy
659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
01:40Cell-mediated Immune Responses
72.2K
Overview
72.2K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
230
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
230